All In Biotech

Drug Trial Radar · NCT00123474

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)

Last checked: Nov 19, 2026Latest source record: Aug 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 724 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

724

Actual

Start

Jul 2005

Primary completion

Sep 2006

Study completion Jul 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).

Conditions

  • Myeloid Leukemia, Chronic, Chronic-Phase

Interventions

  • dasatinibDrug

    Tablets, Oral, 50 mg BID, indefinitely, survival study

  • dasatinibDrug

    Tablets, Oral, 70 mg BID, indefinitely, survival study

  • dasatinibDrug

    Tablets, Oral, 100 mg QD, indefinitely, survival study

  • dasatinibDrug

    Tablets, Oral, 140 mg QD, indefinitely, survival study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-UpTime frame: 6 months

Locations

137 sites in 31 countries. Site status is shown where the registry gives one.

  • University Of Alabama At Birmingham

    Birmingham, Alabama

  • Central Hematology Oncology Medical Group Inc.

    Alhambra, California

  • Pacific Cancer Medical Center Inc

    Anaheim, California

  • Loma Linda University Cancer Center

    Loma Linda, California

  • Pacific Shores Medical Group

    Long Beach, California

  • Ucla Dept. Of Medicine

    Los Angeles, California

  • Ventura County Hematology-Oncology Specialists

    Oxnard, California

  • Kaiser Permanente Medical Center

    Vallejo, California

  • Georgetown University Med Ctr

    Washington D.C., District of Columbia

  • Washington Cancer Institute At Washington Hospital Center

    Washington D.C., District of Columbia

  • University Of Florida

    Gainesville, Florida

  • University Of Miami

    Miami, Florida

  • Md Anderson Cancer Center Orlando

    Orlando, Florida

  • Emory University School Of Medicine

    Atlanta, Georgia

  • Georgia Cancer Specialists

    Atlanta, Georgia

  • Gwinnett Hospital System Inc.

    Lawrenceville, Georgia

  • Northwestern University Feinberg School Of Medicine

    Chicago, Illinois

  • University Of Chicago

    Chicago, Illinois

  • Oncology Hematology Associates Of Central Illinois, Pc

    Peoria, Illinois

  • Indiana University Cancer Center

    Indianapolis, Indiana

  • University Of Kansas Medical Center

    Westwood, Kansas

  • University Of Kentucky

    Lexington, Kentucky

  • University Of Maryland

    Baltimore, Maryland

  • Dana Faber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School Of Medicine

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Devetten, Marcel

    Omaha, Nebraska

  • Nevada Cancer Institute

    Las Vegas, Nevada

  • The Cancer Center At Hackensack University Medical Center

    Hackensack, New Jersey

  • The Cancer Institute Of New Jersey

    New Brunswick, New Jersey

  • New York Presbyterian Hospital

    New York, New York

  • University Of North Carolina At Chapel Hill

    Chapel Hill, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Western Pennsylvania Cancer Institute

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Ut Southwestern Medical Center

    Dallas, Texas

  • The University Of Texas Md Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.